Abstract:Antidepressant drugs such as the serotonin (5-HT)/norepinephrine (NE) and dopamine (DA) reuptake inhibitors activate monoaminergic neurotransmission in various brain regions, such as the amygdala, the frontal cortex or the hippocampus. Although this property is well established, the post-synaptic mechanisms by which these pharmacological agents exert therapeutic activity in major depressive disorders (MDD) is not fully understood. Recent clinical and preclinical studies have indicated that the density and reactivity of glia and more particularly of astrocytes are reduced in MDD patients. These data along with the fact that astrocytes express monoaminergic transporters and receptors make these cells putative targets for antidepressant treatments. Accordingly, in vitro evidence has demonstrated that the application of various classes of antidepressant drugs on rodent primary astrocyte cultures elicits a wide spectrum of responses, from the rise in cytosolic calcium concentrations, as a marker of cellular activity, to the release of glucose metabolites, gliotransmitters and neurotrophic factors. Remarkably, antidepressant drugs also attenuate the release of inflammatory molecules from reactive astrocytes or microglia, suggesting that part of the beneficial effects in depressed patients or animal models of depression might result from the ability of antidepressants to regulate the synthesis and release of psychoactive substances acting on both pre- and post-synaptic neurons. Among the many long-term targets of antidepressant drugs, brainderived neurotrophic factor (BDNF) has been well studied because of the positive influence on adult hippocampal neurogenesis, synaptogenesis and the local serotonergic tone. This review will illustrate how the concept of the tripartite synapse, which is classically associated with different forms of plasticity involving glutamate, could be expanded to the monoaminergic systems to regulate antidepressant drug responses. The recent in vivo data supporting that hippocampal astrocytes act in concert with neurons to release BDNF under pharmacological conditions and thereby regulate different facets of anxiolytic-/antidepressant-like activities through neurogenesis-dependent and independent mechanisms will be emphasized.

Regulation of monoamine transporters: Role of transporter phosphorylation

Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters

Monoamine transporters: vulnerable and vital doorkeepers.

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins

Post-translational mechanisms in psychostimulant-induced neurotransmitter efflux

Structure-Based Specific Detection And Inhibition Of Monoamine Oxidases And Their Applications In Central Nervous System Diseases

Phosphorylation and Sequestration of Serotonin Transporters Differentially Modulated by Psychostimulants

Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response

Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse

General Overview of Organic Cation Transporters in Brain

Endocrine regulation of neurotransmitter transporters

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

Post-translational modifications of transporters

SLC6 neurotransmitter transporters: structure, function, and regulation

Review : Serotonin Transporter and Psychiatric Disorders: Listening to the Gene

Regulation Of Glutamate Transporter Function

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Functional and pathological consequences of being fast on the uptake: Protein kinase G and p38α MAPK regulation of serotonin transporters

Control of serotonin transporter phosphorylation by conformational state

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.